Top

Published in:

01-12-2007 | Original Article

Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma–carcinoma sequence

Authors: Guanglin Cui, Aping Yuan, Rasmus Goll, Trine Olsen, Anne Husebekk, Barthold Vonen, Jon Florholmen

Published in: Cancer Immunology, Immunotherapy | Issue 12/2007

Abstract

Adjacent mucosa may reflect the conflicting of host factors in response to the establishment or invasion of cancers. Characterization of anti-tumor immunity in this region may add help in understanding the immune-related mechanisms of colorectal carcinoma (CRC). In this study, adjacent non-tumor mucosa from 36 patients with colorectal adenoma (CRA), 26 with CRC and normal mucosa from 15 health controls were included, immune cell populations of dendritic cell, lymphocyte and macrophage were characterized with immunohistochemistry (IHC) and tissue messenger RNA (mRNA) levels of Th1 cytokines interferon (IFN)-gamma and its upstream inducers interleukin (IL)-12 and IL-18 were quantified with real-time PCR; In addition, dendritic cell differentiation and function inhibitors cyclooxygenase-2 (COX-2) and IL-6 mRNA levels were also quantified. By IHC, a significant decreased dendritic cell density in the non-tumor mucosa adjacent to CRC was detected (P < 0.05) as compared to the normal controls or adjacent mucosa of CRA. The grading scores for lymphocyte number in the adjacent mucosa of CRA and CRC were gradually non-statistically increased, while the grading scores for macrophages number was not changed. By quantitative real-time PCR, distinct local cytokine gene expression profile was demonstrated. In which, the Th1 cytokines, particularly IL-12, were increased in adjacent mucosa of CRA, but all significantly decreased in adjacent mucosa of CRC. In addition, the mRNA levels of IL-6 and COX-2 were significantly higher in adjacent mucosa of CRC than that in adjacent mucosa of CRA (both P < 0.05). Therefore, dendritic cell functional changes could be one of the important mechanisms for altered anti-tumour immunity in the adjacent non-tumor mucosa throughout adenoma–carcinoma sequence. The increased COX-2 and IL-6 might contribute to dendritic cell funtional defect in adjacent mucosa of CRC.

Fearon ER (1994) Molecular genetic studies of the adenoma–carcinoma sequence. Adv Intern Med 39:123–147PubMed

Fodde R (2002) The APC gene in colorectal cancer. Eur J Cancer 38(7):867–871PubMedCrossRef

Muto T, Nagawa H, Watanabe T, Masaki T, Sawada T (1997) Colorectal carcinogenesis: historical review. Dis Colon Rectum 40(10 Suppl):S80–85PubMedCrossRef

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148PubMedCrossRef

Contasta I, Berghella AM, Pellegrini P, Adorno D (2003) Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18(4):549–557PubMedCrossRef

Contasta I, Pellegrini P, Berghella AM, Beato TD, Adorno D (2006) Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy. Cancer Biother Radiopharm 21(5):488–505PubMedCrossRef

Cui G, Goll G, Olsen T, Steigen S, Husebekk A, Vonen B, Florholmen J (2006) Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum. Cancer Immunol Immunother Dec 8; (Epub ahead of print)

Filipe MI, Mughal S, Bussey HJ (1980) Patterns of mucus secretion in the colonic epithelium in familial polyposis. Invest Cell Pathol 3(4):329–343PubMed

Filipe MI, Cooke KB (1974) Changes in composition of mucin in the mucosa adjacent to carcinoma of the colon as compared with the normal: a biochemical investigation. J Clin Pathol 27(4):315–318PubMedCrossRef

10.

Dawson PA, Filipe MI (1976) An ultrastructural and histochemical study of the mucous membrane adjacent to and remote from carcinoma of the colon. Cancer 37(5):2388–2398PubMedCrossRef

11.

Filipe MI, Branfoot AC (1974) Abnormal patterns of mucus secretion in apparently normal mucosa of large intestine with carcinoma. Cancer 34(2):282–290PubMedCrossRef

12.

Shamsuddin AK, Weiss L, Phelps PC, Trump BF (1981) Colon epithelium. IV. Human colon carcinogenesis. Changes in human colon mucosa adjacent to and remote from carcinomas of the colon. J Natl Cancer Inst 66(2):413–419PubMed

13.

Hao CY, Moore DH, Wong P, Bennington JL, Lee NM, Chen LC (2005) Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin Cancer Res 11(4):1400–1407PubMedCrossRef

14.

Hao CY, Moore DH, Chiu YS, Wong P, Bennington JL, Smith AP, Chen LC, Lee NM (2005) Altered gene expression in normal colonic mucosa of individuals with polyps of the colon. Dis Colon Rectum 48(12):2329–2335PubMedCrossRef

15.

Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, Moretto J, Mendes F, Smith AP, Bennington JL, et al (2004) Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 64(10):3694–3700PubMedCrossRef

16.

Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, Bucana CD, Rikita T, Tahara E, Fidler IJ (2000) Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 157(5):1523–1535PubMed

17.

Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, Kitadai Y, Fidler IJ (2003) Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9(13):4802–4810PubMed

18.

Fox SH, Whalen GF, Sanders MM, Burleson JA, Jennings K, Kurtzman S, Kreutzer D (1998) Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 69(4):230–234PubMedCrossRef

19.

Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Rasmus G (2006) Improvement of real-time PCR for quantifying TNF-a mRNA expression in inflamed colorectal mucosa-An approach to optimize procedures for clinical use. Scand J Clin Lab Invest 66(3):249–259PubMedCrossRef

20.

Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755–1766PubMed

21.

Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1):230–237PubMedCrossRef

22.

Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh AJ, Scheper RJ, de Gruijl TD (2002) Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168(9):4333–4343PubMed

23.

Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, et al (2003) Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9(3):961–968PubMed

24.

Suzuki N, Yoshida A, Nakano Y (2005) Quantitative analysis of multi-species oral biofilms by TaqMan Real-Time PCR. Clin Med Res 3(3):176–185PubMedCrossRef

25.

Cui G, Koh TJ, Chen D, Zhao CM, Takaishi S, Dockray GJ, Varro A, Rogers AB, Fox JG, Wang TC (2004) Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. Cancer Res 64(22):8160–8166PubMedCrossRef

26.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491–3494PubMed

27.

Schwaab T, Weiss JE, Schned AR, Barth RJ Jr (2001) Dendritic cell infiltration in colon cancer. J Immunother 24(2):130–137CrossRef

28.

Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46(1):33–57PubMedCrossRef

29.

Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN (1998) Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4(3):585–593PubMed

30.

Botella-Estrada R, Dasi F, Ramos D, Nagore E, Herrero MJ, Gimenez J, Fuster C, Sanmartin O, Guillen C, Alino S (2005) Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res 15(2):99–106PubMedCrossRef

31.

Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11(1):107–112PubMed

32.

Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S (2000) The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46(Suppl):S52–S61PubMedCrossRef

33.

Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86(3):231–245PubMedCrossRef

34.

Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19(3):247–258PubMedCrossRef

35.

O'Sullivan C, Lewis CE (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172(3):229–235PubMedCrossRef

36.

Lenahan C, Avigan D (2006) Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res 8(1):101PubMedCrossRef

37.

Underwood JC (1974) Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30(6):538–548PubMed

38.

Dave BJ, Hopwood VL, Hughes JI, Jackson GL, Melillo D, Pathak S (1993) Cytogenetic abnormalities in colon cancer patients: a comparison of T- and B-lymphocytes. Anticancer Res 13(2):433–438PubMed

39.

Chaux P, Moutet M, Faivre J, Martin F, Martin M (1996) Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74(5):975–983PubMed

Title: Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma–carcinoma sequence
Authors: Guanglin Cui
Aping Yuan
Rasmus Goll
Trine Olsen
Anne Husebekk
Barthold Vonen
Jon Florholmen
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 12/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0345-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2007

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity

Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer

Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide

Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer